Therapy Areas: Inflammatory Diseases
Qilian International receives approval from Gansu Provincial Drug Administration for sale of nitrofurantoin enteric-coated tablets
20 January 2022 -

Qilian International Holding Group Limited (Nasdaq: QLI), a China-based pharmaceutical and chemical products manufacturer, announced on Wednesday that it has received approval from Gansu Provincial Drug Administration for the sale of its newly developed nitrofurantoin enteric-coated tablets.

The tablets are intended to treat acute lower urinary tract infections caused by bacteria such as Escherichia coli, Enterococcus, Staphylococcus, Klebsiella, and Enterobacter. Nitrofurantoin enteric-coated tablets can also be used to prevent urinary tract infections and are commonly used as anti-inflammatory and bactericidal drugs.

Qilian's tablets have passed the on-site inspection and comprehensive assessment by the Examination and Inspection Center of the Gansu Provincial Drug Administration. As a result of the foregoing approvals, the firm's nitrofurantoin enteric-coated tablets have been determined by the applicable authorities to meet the national drug standards.

Login
Username:

Password: